S-P to pay $165M to settle disclosure law suit

23 March 2009

US firm Schering-Plough is to pay $165.0 million to settle a securities class-action law suit, which alleges that the drug major did  not disclose manufacturing problems to investors. The money will go to a  fund for shareholders who purchased stock in the company between May  2000 and February 2001. S-P denies any wrongdoing and claims that  investors knew about the problems, which were disclosed in Securities  and Exchange Commission filings, but says it will settle the case to  avoid a drawn-out and costly legal battle. It adds that insurance and  existing reserves will cover the payment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight